Duca, Jose, Jansen, Hanneke, Schneider, Petra, Walters, W. Patrick, Plowright, Alleyn T., Sieroka, Norman , Fisher, Jasmin , Listgarten, Jennifer , Goodnow, Jr., Robert A. , Rush, Thomas S. , Zentgraf, Matthias , Hill, John Edward , Krutoholow, Elizabeth , Kohler, Matthias , Luebkemann, Chris, Blaney, Jeff , Funatsu, Kimito and Schneider, Gisbert (2019) Rethinking drug design in the artificial intelligence era. Nature Reviews Drug Discovery. ISSN 14741784

Abstract

Artificial intelligence (AI) tools are increasingly being applied in drug discovery. While some protagonists point to vast opportunities potentially offered by such tools, others remain sceptical, waiting for a clear impact to be shown in drug discovery projects. The reality is probably somewhere in-between these extremes, yet it is clear that AI is providing new challenges not only for the scientists involved but also for the biopharma industry and its established processes for discovering and developing new medicines. This article presents the views of a diverse group of international experts on the ‘grand challenges’ in small-molecule drug discovery with AI and the approaches to address them.

Item Type:	Article
Date Deposited:	08 Feb 2020 00:45
Last Modified:	08 Feb 2020 00:45
URI:	https://oak.novartis.com/id/eprint/39723